HCA Healthcare (NYSE:HCA) Stock Rating Upgraded by BMO Capital Markets

HCA Healthcare (NYSE:HCA) was upgraded by BMO Capital Markets to a “strong-buy” rating in a research note issued to investors on Tuesday, Zacks reports.

A number of other analysts also recently commented on the company. Royal Bank Of Canada restated an “outperform” rating and set a $435.00 price objective on shares of HCA Healthcare in a report on Tuesday, September 8th. Oppenheimer dropped their price target on HCA Healthcare from $520.00 to $485.00 and set an “outperform” rating for the company in a research note on Monday, July 27th. UBS Group decreased their target price on HCA Healthcare from $635.00 to $579.00 and set a “buy” rating for the company in a report on Monday, July 27th. Leerink Partners reaffirmed an “outperform” rating and set a $492.00 price target on shares of HCA Healthcare in a research report on Friday, September 18th. Finally, TD Cowen cut their target price on shares of HCA Healthcare from $500.00 to $431.00 and set a “buy” rating on the stock in a research note on Monday, June 22nd. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $463.70.

HCA Healthcare Trading Down 0.3%

NYSE HCA opened at $436.71 on Tuesday. HCA Healthcare has a twelve month low of $353.99 and a twelve month high of $556.52. The business’s 50-day moving average price is $409.76 and its 200 day moving average price is $426.80. The company has a market capitalization of $94.55 billion, a PE ratio of 14.62, a price-to-earnings-growth ratio of 1.48 and a beta of 1.10.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings data on Friday, July 24th. The company reported $7.59 earnings per share for the quarter, topping the consensus estimate of $7.56 by $0.03. HCA Healthcare had a net margin of 8.77% and a negative return on equity of 244.79%. The business had revenue of $20.23 billion for the quarter, compared to analyst estimates of $19.76 billion. During the same period in the prior year, the firm posted $6.84 EPS. The company’s revenue was up 8.7% on a year-over-year basis. Equities analysts predict that HCA Healthcare will post 29.42 EPS for the current year.

Institutional Trading of HCA Healthcare

Institutional investors and hedge funds have recently bought and sold shares of the company. MidFirst Bank bought a new stake in shares of HCA Healthcare in the 2nd quarter valued at approximately $28,000. Clearstead Trust LLC bought a new stake in HCA Healthcare during the second quarter valued at $29,000. Cedar Mountain Advisors LLC acquired a new stake in shares of HCA Healthcare during the first quarter worth $33,000. MCF Advisors LLC grew its position in shares of HCA Healthcare by 213.0% during the 4th quarter. MCF Advisors LLC now owns 72 shares of the company’s stock valued at $34,000 after buying an additional 49 shares during the last quarter. Finally, Basepoint Wealth LLC bought a new position in HCA Healthcare in the fourth quarter worth about $35,000. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare Company Profile

HCA Healthcare, Inc (NYSE:HCA) is a healthcare services company that operates hospitals and other healthcare facilities. Its network provides a broad range of medical services, including emergency care, inpatient and outpatient treatment, surgery, diagnostic services, and maternity care.

The company also operates ambulatory surgery centers, urgent care facilities, physician practices, and other outpatient locations. HCA Healthcare serves patients through facilities located across the United States, as well as through HCA Healthcare UK, its healthcare operations in the United Kingdom.

HCA Healthcare was founded in 1968 by Dr.